KPV
Tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH)
Quick Answer
A very small (3-amino-acid) peptide fragment derived from the C-terminal end of alpha-MSH, studied mainly for anti-inflammatory properties in early-stage research contexts.
Why People Are Interested
A newer entrant in anti-inflammatory peptide discussion, drawing interest specifically because its proposed mechanism doesn't run through the same pathway as other alpha-MSH-derived compounds — mechanistically interesting to researchers even at this early stage.
What People Hope It May Do
Anti-inflammatory support, particularly gut- and skin-related, extrapolated from animal-model research. (Commonly discussed or proposed — not an established, evidence-backed outcome unless separately stated in Human Evidence above.)
Potential / Research Areas
Gut inflammation research (animal models, e.g., colitis models)
Skin inflammation research (early-stage, some topical/animal work)
General anti-inflammatory pathway research
How It May Work
Proposed anti-inflammatory activity potentially independent of the melanocortin-receptor pathway that mediates alpha-MSH's other (e.g., pigmentation) effects — an active and still-developing area of basic research, not an established mechanism.
What Human Research Shows
Minimal to none in the public clinical literature. This is an early-stage research compound, not one with an established human clinical evidence base.
What Preclinical Research Shows
The primary evidence base — rodent inflammatory-disease models.
Six independent readings, not one score. This reflects the volume and stage of research and discussion — it is not a rating of safety or effectiveness.
"Real-World Interest" and "Research Momentum" reflect the volume of public discussion and research activity Element Health Labs has observed — an editorial judgment, not a measured statistic, and not a claim about clinical significance. Anecdotal popularity is not evidence of effectiveness.
What People Report
What Experts Are Saying
Curated commentary specific to KPV is planned as the Expert & Creator Library grows. Being listed there does not imply an expert's endorsement of Element Health Labs.
Clinical Trials
For the current, authoritative list of registered trials involving KPV, search ClinicalTrials.gov directly — trial status changes frequently, and that registry is the source of truth, not a static summary on this page.
Potential Risks & Side Effects
No meaningful human safety data exists publicly.
Regulatory Status
Not FDA-approved. Not in a public late-stage human clinical development pathway as of last review.
Recent development (2026-08-17): On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8-6 (1 abstention) to recommend adding KPV to the FDA's 503A Bulks List, which would let compounding pharmacies legally use it. This is a nonbinding advisory recommendation only — the FDA has not added KPV to that list, nothing about its legal status has actually changed, and it remains not FDA-approved. The FDA must still decide whether to proceed through formal notice-and-comment rulemaking. Worth noting for context: the agency's own scientists reportedly opposed the recommendation, and a majority of the panelists who voted yes reportedly have ties to the peptide industry. Full sourcing in This Week in Peptides.
What We Still Don't Know
Whether any of the animal-model anti-inflammatory findings apply to humans, appropriate dosing, and long-term safety — none of this has meaningful human data yet.
Limitations of Evidence
Early-stage, animal-model-dominated evidence base; any consumer content should frame this compound clearly as a research-interest area, not a usable intervention.
Keep Researching
- Search ClinicalTrials.gov for KPV
- Expert & Creator Library
- This Week in Peptides
- Understanding Your Bloodwork
- Related peptides:
Last reviewed: 2026-08-17 — FDA compounding-list status re-verified (see Recent development above).